Cost-utility analysis of panitumumab use compared with cetuximab and bevacizumab for the first-line therapy of wild-type RAS metastatic colorectal cancer in the Peruvian health system.

被引：0
|
作者：
Milton, Valderrama
Apolaya-Segura, Moises
Montenegro, Paola Catherine
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15171
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15171
引用
收藏
页数：5
相关论文
共 50 条
  • [21] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB VERSUS CETUXIMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN KRAS WILD-TYPE PATIENTS IN THE SUPPLEMENTARY HEALTH CARE SYSTEM IN BRAZIL
    Tsuchiya, C. T.
    Kim, H. S. J.
    Maximo, M. F. M.
    Ramos, L. A.
    VALUE IN HEALTH, 2014, 17 (07) : A641 - A641
  • [22] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
    Souza, P., V
    Zanini, F. E.
    Biglia, L., V
    Kim, H. S.
    Fahham, L.
    VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
  • [23] COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER
    Tikhonova, I
    Hoyle, M.
    Snowsill, T.
    Crathorne, L.
    Varley-Campbell, J.
    Peters, J.
    Briscoe, S.
    Bond, M.
    Huxley, N.
    VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
  • [24] Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy
    Klein-Scory, S.
    Wahner, I.
    Maslova, M.
    Al-Sewaidi, Y.
    Pohl, M.
    Mika, T.
    Ladigan, S.
    Schroers, R.
    Baraniskin, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S229 - S229
  • [25] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [26] Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States
    Gathirua-Mwangi, Wambui Grace
    Sethi, Harsheen
    Afable, Manuel Geroy
    Bhattacharyya, Devarshi
    Khan, Taha
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1164 - 1172
  • [27] Cost-effectiveness of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
    Van Oostrum, Ilse
    Hu Yannan
    Yuan Zijiao
    Schlichting, Michael
    Tao Libo
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [28] Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease
    Rivera, F.
    Peeters, M.
    Douillard, J-Y.
    Taieb, J.
    Koukakis, R.
    Demonty, G.
    Siena, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [30] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
12345